Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Daily News

Cardiac Biomarkers Equally Apt to Rise in COVID-19, Influenza

Todd Neale

July 25, 2025

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Opinion CV Team Dispatch

July 2023 News Roundup

L.A. McKeown

July 01, 2023

News Daily News

REPLACE COVID Bolsters Advice to Continue RAAS Inhibitors in COVID-19 Patients

Todd Neale

January 13, 2021

News Opinion Editor's Corner

The Biggest News of 2020: TCTMD’s Top 10

Shelley Wood

December 28, 2020

News Conference News ESC 2020

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

Michael O'Riordan

September 04, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2020

Shelley Wood

June 04, 2020

News Daily News

US Prescriptions During COVID-19: Hydroxychloroquine Soars, CVD Drugs Stable

Shelley Wood

May 29, 2020

News Daily News

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

Yael L. Maxwell

May 21, 2020

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

News Conference News ESC 2019

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Yael L. Maxwell

September 04, 2019

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

Advertisement

Cardiac Biomarkers Equally Apt to Rise in COVID-19, Influenza

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

July 2023 News Roundup

REPLACE COVID Bolsters Advice to Continue RAAS Inhibitors in COVID-19 Patients

The Biggest News of 2020: TCTMD’s Top 10

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

TCTMD’s Top 10 Most Popular Stories for May 2020

US Prescriptions During COVID-19: Hydroxychloroquine Soars, CVD Drugs Stable

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content